NeoStem is building a dominant IP portfolio within the field of cell therapy to protect its cutting edge technologies. Notably, this patent estate includes composition of matter patents for AMR-001 (2028) and Athelos (2023). Our patent estate includes 31 issued patents, 54 pending patent applications, including composition of matter and method claims, and a geographic breadth of filings. NeoStem’s IP portfolio focuses on immunology, cardiology, orthopedic, wound healing, stem cell isolation and purification, and VSELTM treatment indications.
Cardiovascular Disease Platform: Amorcyte Patents and Pending Patents
We have 4 issued U.S. patents and 8 O.U.S. patents covering AMR-001, the claims of which are currently scheduled to expire between 2026 and 2030, and we have 24 patent applications pending worldwide. Specifically:
- U.S. Patent No. 7,794,705 covering a chemotactic stem cell product enriched for CD34+ cells that treats injury from AMI;
- U.S. Patent No. 8,088,370 covering the use of AMR-001 in the repair of injury caused by vascular insufficiency, including all forms of cardiac insufficiency, such as congestive heart failure, chronic myocardial ischemia and, we believe, vascular insufficiency induced ischemic conditions beyond the cardiac setting;
- U.S. Patent Nos. 8,343,485 and 8,425,899 offering expanded breadth in AMR’s composition and treatment methods in the vascular insufficiency setting.
Autoimmune Disorders Platform: Athelos Patents and Pending Patents
- In-licensed from the University of Pennsylvania and the University of Southern California the exclusive world-wide rights to a broad patent estate comprised of approximately 21 issued patents and 6 pending patent applications.
- Athelos holds composition of matter patents and method patents, mostly relating to the isolation and expansion of Regulatory T cells, as well as methods of treatment using T cells.
Tissue Regeneration Platform: NeoStem Patents Pending
- In-licensed from the University of Louisville the world-wide patent rights and know-how regarding the isolation, purification and therapeutic use of very small embryonic-like (VSELTM) stem cells.
- In-licensed rights to therapeutic stem cell treatments for wound healing.
- Joint inventorship with the University of Michigan using VSELsTM for the repair and regeneration of bone tissue.
- Joint inventorship with Schepens Eye Research Institute using VSELsTM for treatment of ocular damage.
Information accurate as of June 10, 2013.